Jasleen Kaur, PA-C | |
17002 Gleneagle Dr S, Conroe, TX 77385-4614 | |
(832) 447-7123 | |
Not Available |
Full Name | Jasleen Kaur |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 17002 Gleneagle Dr S, Conroe, Texas |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962913129 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | PA11611 (Texas) | Secondary |
363A00000X | Physician Assistant | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jasleen Kaur, PA-C 17002 Gleneagle Dr S, Conroe, TX 77385-4614 Ph: (832) 447-7123 | Jasleen Kaur, PA-C 17002 Gleneagle Dr S, Conroe, TX 77385-4614 Ph: (832) 447-7123 |
News Archive
BioGenes GmbH, a specialist in sophisticated antibody development, has been chosen as a new partner of cNEUPRO. cNEUPRO is a EU funded research project to analyse neurodegenerative diseases and discover novel biomarkers, and so improve early and differential diagnosis of Alzheimer's dementia.
In a new study currently available on the medRxiv* preprint server, US researchers report the detection of a specific sub-lineage of B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant harboring a novel S:D178H mutation and elucidate its transmission and evolutionary patterns.
USDA's fresh produce chief will join FDA to help develop new food safety rules, as part of a cooperative initiative between FDA and the U.S. Department of Agriculture (USDA).
iMDsoft®, a global leader in hospital-wide clinical information systems, and Dominion, a leading provider of technology solutions in Spain and Latin America, have announced an agreement whereby Dominion will distribute iMDsoft's MetaVision® suite of solutions in Spain.
New research is providing a deeper understanding of how individual actions - such as exercising, sensory stimulation, or drinking - influence brain health and outcomes. This new knowledge could ultimately lead to interventions in age-related cognitive declines, drug abuse, stroke, and brain injury, separate from or in combination with traditional pharmacological approaches. These findings were presented at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.
› Verified 8 days ago